As of Friday close, Twist Bioscience Corporation’s (NASDAQ:TWST) stock was up $4.8, moving up 16.28 percent to $34.29. The average number of shares traded per day over the past five days has been 1,924,880 shares. 3 times new highs have been achieved over the past 5 days, with a $2.90 gain in that time frame. In the last twenty days, the average volume was 1,231,505, while in the previous 50 days, it was 976,092.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, TWST stock retreated -24.05%. Shares of the company fell to $25.88 on 05/12/22, the lowest level in the past month. A 52-week high of $139.99 was reached on 01/04/22 after having rallying from a 52-week low of $25.88. Since the beginning of this year, TWST’s stock price has dropped by -55.69% or -$43.10, and marked a new high 2 times. However, the stock has declined by -75.51% since its 52-week high.
Twist Bioscience Corporation (TWST) last reported insider trading activity 3 days ago on May 11. BARTHELEMY NICOLAS, the Director of the company, purchased of 8,550 shares for $29.25 on May 11. It resulted in a $250,096 investment by the insider. Banyai William sold 378 shares at an average price of $33.98 on Apr 25. The insider now owns 261,876 shares following the transaction. On Apr 14, Chief Financial Officer THORBURN JAMES M sold 6,620 shares at $42.85 apiece. The transaction was valued at $283,683.
The stock’s beta is 1.19. Besides these, the trailing price-to-sales (P/S) ratio of 12.86, the price-to-book (PB) ratio of 2.73.
In the three months ended September 29, Twist Bioscience Corporation’s quick ratio stood at 4.30, while its current ratio was 4.80, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 38.80% percent. Based on annual data, TWST earned $51.71 million in gross profit and brought in $132.33 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -25.90%. Return on equity (ROE) for the past 12 months was -25.00%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. TWST’s revenue rose 35.18% to $42.02 million during the quarter, while net income inched up to $48.13 million. While analysts expected Twist Bioscience Corporation to report -$0.79 quarterly earnings, the actual figure was -$0.84 per share, beating the consensus estimate by -6.30%. During the quarter, the company generated -$56.83 million in EBITDA. The liabilities of Twist Bioscience Corporation were 158.28 million at the end of its most recent quarter ended September 29, and its total debt was $72.97 million. The value of shareholders’ equity is $56.26 million.
This quick technical analysis looks at Twist Bioscience Corporation’s (TWST) price momentum. With a historical volatility rate of 142.67%, the RSI 9-day stood at 54.07% on 13 May.
With respect to its five-day moving average, the current Twist Bioscience Corporation price is up by +9.24% percent or $2.90. At present, TWST shares trade -19.49% below its 20-day simple moving average and -58.05% percent below its 100-day simple moving average. However, the stock is currently trading approximately -34.52% below its SMA50 and -71.20% below its SMA200.
Stochastic coefficient K was 43.40% and Stochastic coefficient D was 23.71%, while ATR was 3.91. Given the Stochastic reading of 87.42% for the 14-day period, the RSI (14) reading has been calculated as 47.83%. As of today, the MACD Oscillator reading stands at -0.67, while the 14-day reading stands at -0.52.
Twist Bioscience Corporation (TWST) has been rated Hold by analysts. According to 1 brokerage firm, TWST is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 2 analysts rate Twist Bioscience Corporation stock as buy, with 2 recommending it as overweight.